End-of-day quote
Shanghai S.E.
03:30:00 29/05/2024 am IST
|
5-day change
|
1st Jan Change
|
22.82
CNY
|
-0.57%
|
|
-5.86%
|
-28.73%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
42,401
|
21,257
|
12,808
|
9,060
|
-
|
Enterprise Value (EV)
1 |
42,401
|
21,257
|
12,808
|
9,060
|
9,060
|
P/E ratio
|
56.7
x
|
35.7
x
|
-178
x
|
18.9
x
|
21.4
x
|
Yield
|
-
|
2.35%
|
0.31%
|
1.31%
|
1.31%
|
Capitalization / Revenue
|
22.7
x
|
5.96
x
|
9.96
x
|
5.66
x
|
4.5
x
|
EV / Revenue
|
22.7
x
|
5.96
x
|
9.96
x
|
5.66
x
|
4.5
x
|
EV / EBITDA
|
51.1
x
|
24.3
x
|
169
x
|
20.6
x
|
14.4
x
|
EV / FCF
|
-
|
-10,02,16,237
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
-
|
Price to Book
|
10.3
x
|
4.61
x
|
3.18
x
|
1.99
x
|
1.88
x
|
Nbr of stocks (in thousands)
|
4,00,010
|
4,00,010
|
4,00,010
|
3,96,999
|
-
|
Reference price
2 |
106.0
|
53.14
|
32.02
|
22.82
|
22.82
|
Announcement Date
|
25/02/22
|
27/02/23
|
28/02/24
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
1,869
|
3,569
|
1,286
|
1,600
|
2,011
|
EBITDA
1 |
830.3
|
875.7
|
75.74
|
439.4
|
631.2
|
EBIT
1 |
771.1
|
717.5
|
-100.2
|
290.8
|
430.4
|
Operating Margin
|
41.27%
|
20.1%
|
-7.79%
|
18.17%
|
21.4%
|
Earnings before Tax (EBT)
1 |
764.4
|
609.4
|
-115.7
|
246.7
|
394.7
|
Net income
1 |
678.3
|
594.2
|
-70.96
|
485.7
|
467.3
|
Net margin
|
36.3%
|
16.65%
|
-5.52%
|
30.35%
|
23.24%
|
EPS
2 |
1.870
|
1.490
|
-0.1800
|
1.210
|
1.068
|
Free Cash Flow
|
-
|
-212.1
|
-
|
-
|
-
|
FCF margin
|
-
|
-5.94%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
1.250
|
0.1000
|
0.3000
|
0.3000
|
Announcement Date
|
25/02/22
|
27/02/23
|
28/02/24
|
-
|
-
|
Fiscal Period: December |
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
-
|
268.8
|
298.3
|
EBITDA
|
-
|
-
|
-
|
EBIT
1 |
-
|
-40
|
9.534
|
Operating Margin
|
-
|
-14.88%
|
3.2%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-1.293
|
Net income
1 |
-50.62
|
-
|
4.704
|
Net margin
|
-
|
-
|
1.58%
|
EPS
2 |
-0.1300
|
-0.0700
|
0.0100
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
26/04/23
|
29/08/23
|
28/10/23
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-212
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
40.5%
|
13.6%
|
-1.55%
|
10.1%
|
8.47%
|
ROA (Net income/ Total Assets)
|
21.9%
|
11.2%
|
-
|
3.8%
|
6.5%
|
Assets
1 |
3,103
|
5,306
|
-
|
12,783
|
7,189
|
Book Value Per Share
2 |
10.30
|
11.50
|
10.10
|
11.50
|
12.10
|
Cash Flow per Share
2 |
1.540
|
1.840
|
0.3800
|
0.7100
|
1.340
|
Capex
1 |
259
|
947
|
219
|
371
|
432
|
Capex / Sales
|
13.87%
|
26.54%
|
17.06%
|
23.21%
|
21.48%
|
Announcement Date
|
25/02/22
|
27/02/23
|
28/02/24
|
-
|
-
|
Last Close Price
22.82
CNY Average target price
35.72
CNY Spread / Average Target +56.53% Consensus |
1st Jan change
|
Capi.
|
---|
| -28.73% | 125.74Cr | | +39.22% | 73TCr | | +30.57% | 59TCr | | -7.85% | 35TCr | | +15.48% | 32TCr | | -0.12% | 27TCr | | +12.55% | 24TCr | | +6.65% | 20TCr | | -6.09% | 20TCr | | -3.37% | 16TCr |
Other Pharmaceuticals
|